ENLV Earnings & Financial Statements
Enlivex Therapeutics Ltd.
$0.34
-$0.02(-6.02%)
43
Overall
80
Value
27
Tech
23
Quality
Market Cap
$7.21M
Volume
409.25K
52W Range
$0.38 - $27.15
Target Price
$80.00
ENLV earnings and financial statements: Enlivex Therapeutics Ltd.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ENLV Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cost of revenue | - | - | - | - | $126.0K |
| Operating income | -$15.03M | -$15.89M | -$25.80M | -$25.80M | -$19.29M |
| EBITDA | $1.62B | -$14.47M | -$19.76M | -$25.02M | -$18.74M |
| Net income | $1.24B | -$15.01M | -$20.53M | -$31.06M | -$14.47M |
| EPS (diluted) | $25.48 | $-0.73 | $-1.69 | $-1.69 | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $2.33B | $27.69M | $36.83M | $67.64M | $95.15M |
| Total liabilities | $392.05M | $4.10M | $6.75M | $10.80M | $10.11M |
| Shareholders’ equity | $1.93B | $23.59M | $30.08M | $56.84M | $85.04M |
| Cash and equivalents | $5.75M | $23.50M | $27.32M | $49.95M | $11.20M |
| Long-term debt | $383.0K | $299.0K | - | $4.19M | $5.39M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.42M | -$13.01M | -$23.95M | -$23.95M | -$17.54M |
| Capital expenditure | - | - | - | -$8.12M | -$1.63M |
| Free cash flow | -$10.48M | -$13.11M | -$32.08M | -$32.08M | -$19.17M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENLV | $0.34 | -6.0% | 409.25K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enlivex Therapeutics Ltd. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW